New triple therapy aims to control advanced breast cancer with fewer side effects
Disease control
Recruiting now
This study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the triple combination is safe and can reduce high blood sugar side effects often caused by the standard drugs. About 52 adul…
Phase: PHASE1, PHASE2 • Sponsor: SynDevRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC